Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 87.7%

Neg 0% Neu 0% Pos 87.7%

Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.